ストックスクリーナーアプリを入手
428.78
0.01%
0.6374
前日終値:
$428.14
開ける：
$429.33
24時間の取引高:
533.81K
Relative Volume:
0.53
時価総額：
$56.25B
収益：
$2.46B
当期純損益:
$-319.09M
株価収益率:
-173.59
EPS:
-2.47
ネットキャッシュフロー:
$-52.09M
1週間 パフォーマンス:
+9.16%
1か月 パフォーマンス:
+32.10%
6か月 パフォーマンス:
+55.03%
1年 パフォーマンス:
+64.57%
1日の値動き範囲:
$425.81
$436.77
1週間の範囲:
$382.19
$436.77
52週間の値動き範囲:
$205.87
$436.77
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
429.12 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.97 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.46 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
669.59 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.21 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD - Investing.com
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference - Business Wire
Analyst Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher - Yahoo Finance
U.S. Transthyretin Amyloidosis Treatment Market Exclusive - openPR.com
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
Wolfe Research upgrades Alnylam Pharmaceuticals stock rating to Peerperform By Investing.com - Investing.com Canada
Oppenheimer upgrades Alnylam stock to Outperform on strong Amvuttra sales By Investing.com - Investing.com Canada
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain? - Yahoo Finance
Alnylam’s Amvuttra Sales Leave Forecasts In The Dust - Finimize
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
Why Alnylam Pharmaceuticals (ALNY) Is Up 23.7% After Raising 2025 Revenue Outlook on AMVUTTRA Growth - simplywall.st
What are analysts’ price targets for Alnylam Pharmaceuticals Inc. in the next 12 monthsTremendous growth potential - Jammu Links News
When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthDiscover top stock picks for aggressive growth - Jammu Links News
How does Alnylam Pharmaceuticals Inc. compare to its industry peersUnmatched market performance - Jammu Links News
What are the latest earnings results for Alnylam Pharmaceuticals Inc.Free Capital Efficiency Planning - Jammu Links News
Does Alnylam Pharmaceuticals Inc. stock perform well during market downturnsCapitalize on momentum-driven investment opportunities - Jammu Links News
How does Alnylam Pharmaceuticals Inc. generate profit in a changing economyConsistently superior profits - Jammu Links News
What makes Alnylam Pharmaceuticals Inc. stock price move sharplyUnlock powerful stock screening tools today - Jammu Links News
How volatile is Alnylam Pharmaceuticals Inc. stock compared to the marketCapitalize on strong market momentum - Jammu Links News
Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastMaximize gains with strategic stock entries - Jammu Links News
What are the technical indicators suggesting about Alnylam Pharmaceuticals Inc.Discover the fastest growing stocks today - Jammu Links News
Published on: 2025-08-03 13:52:50 - Jammu Links News
What catalysts could drive Alnylam Pharmaceuticals Inc. stock higher in 2025Exceptional risk-adjusted gains - Jammu Links News
Alnylam Pharmaceuticals' Q2 2025: Unraveling Key Contradictions in AMVUTTRA's Market Strategy and Patient Access - AInvest
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - MSN
Alnylam Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Is it the right time to buy Alnylam Pharmaceuticals Inc. stockBreakout Stocks Signals Backed By Experts - jammulinksnews.com
Alnylam’s Q2 2025 Earnings Call Highlights Robust Growth - TipRanks
BMO Capital Reaffirms Buy Rating on Alnylam Pharma with $450 Price Target - AInvest
Alnylam Pharmaceuticals Sees Strong Sales of Rare Disease Drug, Raises Revenue Guidance - AInvest
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance - AOL.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Alnylam projects $2.65B–$2.8B 2025 revenue following AMVUTTRA ATTR-CM launch momentum - MSN
Why Is Alnylam Stock Gaining Friday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga
Alnylam soars past $50B market cap - The Business Journals
Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - simplywall.st
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates - MSN
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Has Found A Path To Profitability - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2025 Earnings Call Transcript - Insider Monkey
‘Very Impressive’ Amvuttra ATTR-CM Sales Send Alnylam Soaring - BioSpace
Narrow-Moat Alnylam's Strong Launch of Amvuttra for ATTR-CM Drives Growth; Pipeline Makes Progress - Morningstar
Alnylam Pharmaceuticals Lifts Revenue Outlook After Earnings Beat - Finimize
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - BioSpace
Alnylam Advances Key Programs to Achieve Profitability Goals - AInvest
Alnylam Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 292% - AInvest
Alnylam Pharmaceuticals Inc (ALNY) Q2 2025 Earnings Call Highlig - GuruFocus
Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
Alnylam Pharmaceuticals Inc (ALNY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Option Exercise |
118.73 |
19,297 |
2,291,057 |
68,245 |
| Greenstreet Yvonne | Chief Executive Officer |
May 30 '25 |
Sale |
304.39 |
31,640 |
9,630,902 |
48,948 |
| Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Sale |
306.00 |
19,297 |
5,904,882 |
48,948 |
1.75%
0.55%
大文字化:
|
ボリューム (24 時間):